Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559850 | 0.82 | NPY5R (0.46) | USP30 | |
| SCHEMBL3567422 | 0.80 | HPGD (0.49) | NPC1SMN1; SMN2HPGDADORA3ADORA2A | |
| SCHEMBL3567395 | 0.79 | CDK2 (0.53) | NPC1SMN1; SMN2HPGDADORA3ADORA2A | |
| SCHEMBL3560570 | 0.71 | CDK2 (0.45) | NPC1SMN1; SMN2HPGDADORA3ADORA2A | |
| SCHEMBL3567427 | 0.68 | ALDH1A1 (0.49) | NPC1SMN1; SMN2HPGDADORA3ADORA2A | |
| SCHEMBL30642212 | 0.66 | JAK2 (0.64) | NPC1SMN1; SMN2HPGDALDH1A1KDM4E | |
| SCHEMBL16503904 | 0.64 | HPGD (0.67) | NPC1HPGDALDH1A1KDM4EPOLB | |
| SCHEMBL5105437 | 0.64 | MAPK1 (0.53) | NPC1SMN1; SMN2HPGDADORA3ADORA2A | |
| SCHEMBL8272416 | 0.64 | MAPK1 (0.53) | NPC1SMN1; SMN2HPGDADORA3ADORA2A | |
| SCHEMBL21348455 | 0.63 | NPC1 (0.56) | NPC1SMN1; SMN2HPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671072-B2 | Aminopyrazole derivatives as GSK-3 inhibitors | PFIZER INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | BENBOW JOHN W | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276010-A1 | Aminopyrazole Derivatives as Gsk-3 Inhibitors | GSK3B, GSK3A, GSKIP | NPC1 2332/4885SMN1; SMN2 3262/4885HPGD 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.